Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
Pranav MurthyMazen S ZenatiAmr I Al AbbasCaroline J RieserNathan BaharyMichael T LotzeHerbert J ZehAmer H ZureikatBrian A BoonePublished in: Annals of surgical oncology (2019)
Post-treatment SII may be a useful prognostic marker in PDAC patients receiving NAT.